SciNeuro and Eli Lilly sign exclusive license agreement for alpha-synuclein in Greater China

Alpha-synuclein therapies may exhibit efficacy in Parkinson’s disease and other similar neurological disorders. Credit: Jesse Orrico/Unsplash.